JP2020520987A5 - - Google Patents

Download PDF

Info

Publication number
JP2020520987A5
JP2020520987A5 JP2019565468A JP2019565468A JP2020520987A5 JP 2020520987 A5 JP2020520987 A5 JP 2020520987A5 JP 2019565468 A JP2019565468 A JP 2019565468A JP 2019565468 A JP2019565468 A JP 2019565468A JP 2020520987 A5 JP2020520987 A5 JP 2020520987A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
infection
lungs
gram
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019565468A
Other languages
English (en)
Japanese (ja)
Other versions
JP7210476B2 (ja
JP2020520987A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/033963 external-priority patent/WO2018217808A1/en
Publication of JP2020520987A publication Critical patent/JP2020520987A/ja
Publication of JP2020520987A5 publication Critical patent/JP2020520987A5/ja
Application granted granted Critical
Publication of JP7210476B2 publication Critical patent/JP7210476B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019565468A 2017-05-22 2018-05-22 リポ‐グリコペプチド可切断性誘導体及びその使用 Active JP7210476B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762509378P 2017-05-22 2017-05-22
US62/509,378 2017-05-22
US201762518280P 2017-06-12 2017-06-12
US62/518,280 2017-06-12
US201762560413P 2017-09-19 2017-09-19
US62/560,413 2017-09-19
PCT/US2018/033963 WO2018217808A1 (en) 2017-05-22 2018-05-22 Lipo-glycopeptide cleavable derivatives and uses thereof

Publications (3)

Publication Number Publication Date
JP2020520987A JP2020520987A (ja) 2020-07-16
JP2020520987A5 true JP2020520987A5 (cg-RX-API-DMAC7.html) 2021-07-26
JP7210476B2 JP7210476B2 (ja) 2023-01-23

Family

ID=64395938

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019565425A Active JP7165146B2 (ja) 2017-05-22 2018-05-22 グリコペプチド誘導体化合物およびそれらの使用
JP2019565468A Active JP7210476B2 (ja) 2017-05-22 2018-05-22 リポ‐グリコペプチド可切断性誘導体及びその使用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2019565425A Active JP7165146B2 (ja) 2017-05-22 2018-05-22 グリコペプチド誘導体化合物およびそれらの使用

Country Status (11)

Country Link
US (3) US11071769B2 (cg-RX-API-DMAC7.html)
EP (2) EP3630154A4 (cg-RX-API-DMAC7.html)
JP (2) JP7165146B2 (cg-RX-API-DMAC7.html)
KR (2) KR102661786B1 (cg-RX-API-DMAC7.html)
CN (2) CN110996984A (cg-RX-API-DMAC7.html)
AU (2) AU2018271873B2 (cg-RX-API-DMAC7.html)
BR (2) BR112019024549A2 (cg-RX-API-DMAC7.html)
GB (2) GB2577420B (cg-RX-API-DMAC7.html)
IL (2) IL270686B (cg-RX-API-DMAC7.html)
NZ (2) NZ758836A (cg-RX-API-DMAC7.html)
WO (2) WO2018217800A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0811530B1 (pt) 2007-05-14 2019-01-02 Research Foundation Of State Univ Of New York composição compreendendo indutor(es) de resposta fisiológica à dispersão ácido decanóico, superfície, solução, método ex vivo de tratamento ou inibição da formação de um biofilme sobre uma superfície
KR102661786B1 (ko) 2017-05-22 2024-04-26 인스메드 인코포레이티드 글리코펩티드 유도체 화합물 및 이의 용도
NL2023883B1 (en) * 2019-09-24 2021-04-26 Univ Leiden Antibiotic compounds
US11793808B2 (en) 2021-02-22 2023-10-24 Mannkind Corp. Compositions of clofazimine, combinations comprising them, processes for their preparation, uses and methods comprising them
WO2023094994A1 (en) * 2021-11-24 2023-06-01 Cumberland Pharmaceuticals Inc Methods for the prevention or treatment of anthrax infection

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4639433A (en) 1985-08-14 1987-01-27 Eli Lilly And Company Glycopeptide derivatives
PT86457B (pt) * 1986-12-30 1990-11-20 Smithkline Beecham Corp Processo para a preparacao de glicopeptidos glicosilados e de composicoes que os contem
IT1228459B (it) 1989-02-23 1991-06-19 Phidea S R L Inalatore con svuotamento regolare e completo della capsula.
US5785049A (en) 1994-09-21 1998-07-28 Inhale Therapeutic Systems Method and apparatus for dispersion of dry powder medicaments
PT101450B (pt) 1994-02-02 1999-11-30 Hovione Produtos Farmaceuticos Novo dispositivo para inalacao
US6051256A (en) 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
WO1998029141A1 (en) 1996-12-31 1998-07-09 Inhale Therapeutic Systems, Inc. Processes for spray drying solutions of hydrophobic drugs with hydrophilic excipients and compositions prepared by such processes
JP2001517692A (ja) 1997-09-29 2001-10-09 インヘール セラピューティック システムズ, インコーポレイテッド ネブライザにおける使用のための安定化調製物
WO1999016420A1 (en) 1997-09-29 1999-04-08 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in nebulizers
US6518242B1 (en) * 1998-02-20 2003-02-11 Theravance, Inc. Derivatives of glycopeptide antibacterial agents
CA2319495A1 (en) * 1998-06-08 1999-12-16 Advanced Medicine, Inc. Multibinding inhibitors of microsomal triglyceride transferase protein
UA73924C2 (en) 1998-10-09 2005-10-17 Nektar Therapeutics Device for delivering active agent formulation to lungs of human patient
PL198311B1 (pl) 1998-12-23 2008-06-30 Theravance Związki glikopeptydowe, zawierające je kompozycje farmaceutyczne oraz ich zastosowanie
DE60041610D1 (de) 1999-05-28 2009-04-02 Nektar Therapeutics Gerät zum Abgeben von abgemessenen Mengen von Medikamente beinhaltendem Aerosol
US6606992B1 (en) 1999-06-30 2003-08-19 Nektar Therapeutics Systems and methods for aerosolizing pharmaceutical formulations
US6586008B1 (en) 1999-08-25 2003-07-01 Advanced Inhalation Research, Inc. Use of simple amino acids to form porous particles during spray drying
WO2001057071A2 (en) 2000-02-04 2001-08-09 Advanced Medicine, Inc. Glycopeptide derivatives having antibiotic activity
AU3818001A (en) 2000-02-11 2001-08-20 Lilly Co Eli Selective n-acylation of a82846 glycopeptide analogs
US7442388B2 (en) 2000-05-10 2008-10-28 Weers Jeffry G Phospholipid-based powders for drug delivery
UA75083C2 (uk) * 2000-06-22 2006-03-15 Тераванс, Інк. Похідні глікопептидфосфонатів
TWI312785B (en) * 2001-08-24 2009-08-01 Theravance Inc Process for preparing vancomycin derivatives
WO2004044222A2 (en) * 2002-11-12 2004-05-27 Enzon Pharmaceuticals, Inc. Polymeric prodrugs of vancomycin
US7521418B2 (en) * 2003-05-27 2009-04-21 Theravance, Inc. Use of a polyene macrolide antifungal agent in combination with a glycopeptide antibacterial agent
TWI342312B (en) * 2003-10-22 2011-05-21 Theravance Inc Hydrochloride salts of a glycopeptide phosphonate derivative
US20070185015A1 (en) * 2005-02-28 2007-08-09 Chiron Corporation and North China Pharmaceutical Corporation Semi-synthetic desmethyl-vancomycin-based glycopeptides with antibiotic activity
US7632918B2 (en) * 2005-02-28 2009-12-15 Novartis Vaccines And Diagnostics, Inc. Semi-synthetic glycopeptides with antibiotic activity
BRPI0817311A2 (pt) * 2007-09-25 2015-03-17 Novartis Ag Tratamento de doenças pulmonares com medicamentos em aerossol tais como a vancomicina
JP5855829B2 (ja) * 2007-10-23 2016-02-09 インスメッド, インコーポレイテッド リポソーム化バンコマイシン製剤
WO2009085562A1 (en) * 2007-12-26 2009-07-09 Lead Therapeutics, Inc. Novel semi-synthetic glycopeptides as antibacterial agents
WO2010048340A2 (en) * 2008-10-24 2010-04-29 Lead Therapeutics, Inc. Novel semi-synthetic glycopeptides as antibacterial agents
GB2465863A (en) * 2008-12-05 2010-06-09 Lead Therapeutics Inc Semi-synthetic heptapeptidic glycopeptides for the treatment of bacterial infections
AU2010229721A1 (en) * 2009-03-26 2011-10-06 Pulmatrix, Inc. Methods for treating and preventing pneumonia and ventilator-associated tracheobronchitis
PL2424559T3 (pl) * 2009-04-28 2024-07-29 Melinta Therapeutics, Llc Sposoby leczenia zakażeń bakteryjnych z zastosowaniem orytawancyny
US9572774B2 (en) 2011-05-19 2017-02-21 Savara Inc. Dry powder vancomycin compositions and associated methods
BR112013029803B1 (pt) * 2011-05-19 2021-07-13 Savara, Inc Composições de vancomicina em pó seco
US9879049B2 (en) 2011-08-05 2018-01-30 The Scripps Research Institute Glycopeptide antibiotic analogs effective against vancomycin-resistant bacterial strains
HRP20220158T1 (hr) * 2012-05-21 2022-04-15 Insmed Incorporated Sustavi za liječenje plućnih infekcija
CA2891487A1 (en) * 2012-11-29 2014-06-05 Insmed Incorporated Stabilized vancomycin formulations
GB201402267D0 (en) * 2014-02-10 2014-03-26 Cambridge Entpr Ltd Antibacterial agents
CN105085636B (zh) * 2014-05-19 2020-05-01 中国医学科学院药物研究所 一类万古霉素衍生物、其制备方法及其在抗菌方面的应用
US10577395B2 (en) 2014-07-10 2020-03-03 The Scripps Research Institute N-(hydrophobe-substituted) vancosaminyl [Ψ-[C(=NH) NH] Tpg4] vancomycin and [Ψ-[CH2NH]Tpg4] vancomycin
CN107325159A (zh) 2016-04-29 2017-11-07 中国科学院上海药物研究所 一类万古霉素衍生物、其制备方法、药物组合物和用途
WO2018008197A1 (ja) 2016-07-07 2018-01-11 日東電工株式会社 反射層および蛍光体層付光半導体素子
CA3042039C (en) 2016-10-31 2023-09-26 The Scripps Research Institute Peripheral modifications on pocket-redesigned vancomycin analogs synergistically improve antimicrobial potency and durability
KR102661786B1 (ko) * 2017-05-22 2024-04-26 인스메드 인코포레이티드 글리코펩티드 유도체 화합물 및 이의 용도

Similar Documents

Publication Publication Date Title
JP2020520987A5 (cg-RX-API-DMAC7.html)
JP2016513688A5 (cg-RX-API-DMAC7.html)
RU2018138195A (ru) Соединения 3,5-диамино-6-хлор-n-(n-(4- фенилбутил)карбамимидоил)пиразин-2-карбоксамида
JP2004502752A5 (cg-RX-API-DMAC7.html)
RU2015138796A (ru) Способы и составы для лечения респираторных заболеваний
JP2005523922A5 (cg-RX-API-DMAC7.html)
JP2009538327A5 (cg-RX-API-DMAC7.html)
JP2006182786A5 (cg-RX-API-DMAC7.html)
JP2011520911A5 (cg-RX-API-DMAC7.html)
HRP20151346T1 (hr) 3,5-diamino-6-klor-n-(n-(4-(4-(2-(heksil(2,3,4,5,6-pentahidroksiheksil)amino)etoksi)fenil)butil)karbamimidoil)pirazin-2-karboksamid
JP2016534063A5 (cg-RX-API-DMAC7.html)
JP2010530372A5 (cg-RX-API-DMAC7.html)
JP2015509534A5 (cg-RX-API-DMAC7.html)
JP2011173929A (ja) 呼吸器官の細菌性疾患の処置
JP2013528640A5 (cg-RX-API-DMAC7.html)
JP2018513188A5 (cg-RX-API-DMAC7.html)
JP2016514192A5 (cg-RX-API-DMAC7.html)
JP2023109937A5 (cg-RX-API-DMAC7.html)
JP2009503024A5 (cg-RX-API-DMAC7.html)
Berendt et al. Treatment of respiratory Klebsiella pneumoniae infection in mice with aerosols of kanamycin
RU2015129076A (ru) Арилалкил- и арилоксиалкил-замещенные соединения, блокирующие эпителиальный натриевый канал
JP2018507257A5 (cg-RX-API-DMAC7.html)
JP2020520986A5 (cg-RX-API-DMAC7.html)
JP2014511897A5 (cg-RX-API-DMAC7.html)
JP2017529398A5 (cg-RX-API-DMAC7.html)